<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05082961</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A01862-39</org_study_id>
    <nct_id>NCT05082961</nct_id>
  </id_info>
  <brief_title>Circulating Immunes Cells, Cytokines and Brain Radiotherapy</brief_title>
  <acronym>CYRAD</acronym>
  <official_title>Circulating Immunes Cells, Cytokines and Brain Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Commissariat A L'energie Atomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with malignant tumours of the cephalic pole have a poor prognosis, despite a wide&#xD;
      range of treatments. prognosis despite a large therapeutic arsenal. Among this arsenal,&#xD;
      radiotherapy (RT) is one of the standard treatments for these tumours. However, this&#xD;
      treatment can cause damage to the surrounding healthy tissue, has limited efficacy in hypoxic&#xD;
      However, this treatment can cause damage to the surrounding healthy tissue, has limited&#xD;
      efficacy in hypoxic tissue and can promote pro-tumour inflammation.&#xD;
&#xD;
      In these circumstances, hadrontherapy, which uses charged heavy particles, such as protons or&#xD;
      carbon ions, is the preferred treatment. protons or carbon ions, seems more appropriate for&#xD;
      the treatment of these tumours. However, although inflammation plays a major role in tumour&#xD;
      development and tumour development and therapeutic response, few studies have evaluated the&#xD;
      immune response response after proton therapy (PT) and carbon therapy (CT). The objective of&#xD;
      this project is to study the effect of hadrontherapy on resident/circulating inflammation&#xD;
      after brain irradiation. brain irradiation. In a first step, the impact of different PT and&#xD;
      CT TEL on macrophages (M&amp;#1060;), the most abundant immune cells in malignant solid tumours,&#xD;
      will be evaluated in vitro. malignant solid tumours, will be evaluated in vitro. In a second&#xD;
      step, the evolution of circulating leukocytes after brain irradiation with X-rays or protons&#xD;
      will be studied in vivo in rodents and patients. rodent and patient. In this project, we&#xD;
      propose to study for the first time the inflammatory response after hadrontherapy in the&#xD;
      context of a cephalic tumour. cephalic tumour. These results will allow a better&#xD;
      understanding of the biological response response following PT and CT with the aim of&#xD;
      optimising RT and potentially and potentially translate these data to the clinic.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD8+ T-cell count.</measure>
    <time_frame>up to 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD4+ Lymphocytes T count</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regulatory T cells</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>X-ray photon therapy + biological samples</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Protontherapy + biological samples</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of blood samples</intervention_name>
    <description>Samples to evaluate the circulating CD8+ T cell count.</description>
    <arm_group_label>Protontherapy + biological samples</arm_group_label>
    <arm_group_label>X-ray photon therapy + biological samples</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt; 18 years&#xD;
&#xD;
          -  Head and neck cancer: (upper aerodigestive tract, cavum, facial sinus, skull base,&#xD;
             brain) operated&#xD;
&#xD;
          -  Surgery for complete tumour resection or with microscopic residue R1&#xD;
&#xD;
          -  All possible histologies: squamous cell carcinoma, undifferentiated carcinoma of the&#xD;
             nasopharyngeal type (UCNT), adenocarcinoma, adenoid cystic carcinoma, chordoma,&#xD;
             chondrosarcoma, other tumours&#xD;
&#xD;
          -  Patients undergoing exclusive postoperative radiotherapy with a minimum total dose of&#xD;
             60 Gy of X-ray photon radiation or equivalent proton radiation.&#xD;
&#xD;
          -  Patient affiliated to a social security scheme&#xD;
&#xD;
          -  Signature of the informed consent before any specific procedure related to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Macroscopic postoperative tumour residue R2&#xD;
&#xD;
          -  Previous cancer within 5 years (except treated basal cell skin carcinoma and treated&#xD;
             cervical cancer).&#xD;
&#xD;
          -  Previous radiotherapy (except brachytherapy of the cervix or prostate)&#xD;
&#xD;
          -  Chemotherapy or other systemic oncological treatment (cetuximab) concomitant with&#xD;
             radiotherapy&#xD;
&#xD;
          -  Long-term immunosuppressive or corticosteroid therapy&#xD;
&#xD;
          -  Patient deprived of liberty or under guardianship, protected adult&#xD;
&#xD;
          -  Patient unable to undergo trial monitoring for geographical, social or&#xD;
             psychopathological reasons&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Emergency situations&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mathieu CESAIRE, MD</last_name>
    <phone>+33 (0)2 31 45 50 20</phone>
    <email>m.cesaire@baclesse.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Michel GRELLARD</last_name>
    <phone>+33 (0)2 31 45 50 50</phone>
    <email>jm.grellard@baclesse.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Fran√ßois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathieu Cesaire, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mathieu Cesaire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juliette Thariat, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Florescu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien Geffrelot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernand Missohou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

